Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP2246 for Motor Dysfunction After Late Subacute to Chronic Ischemic Stroke
jRCT2033250653Phase 2Recruiting
- Sponsor
- Astellas Pharma
- Start
- Apr 2026
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ASP2246 in ischemic stroke (4 arms), sponsored by Astellas Pharma. Primary endpoints: Dose-limiting toxicities (DLTs), Treatment-emergent adverse events (TEAEs) and 3 more. Started Apr 2026; status: recruiting.
02
Drugs
ASP2246
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on jRCT2033250653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033250653.